ICH S9: Developing anticancer drugs, one year later

Toxicologic Pathology

Volumn 39, Issue 6, 2011, Pages 913-915

  Ponce, Rafael ^a  

^a AMGEN INC   (United States)

Author keywords

cancer; drug development; preclinical safety assessment risk management

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER THERAPY; CARCINOGENICITY; DRUG HALF LIFE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; NONHUMAN; PATIENT SAFETY; PHARMACODYNAMICS; PHARMACOKINETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTICARCINOGENIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; GUIDELINES AS TOPIC; HUMANS; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80053597510     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311416263     Document Type: Review

References (8)

1. DeGeorge J. J., Ahn C. H., Andrews P. A., Brower M. E., Giorgio D. W., Goheer M. A., Lee-Ham D. Y., McGuinn W. D., Schmidt W., Sun C. J., Tripathi S. C.. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol. 1998 ; 41: 173-85 (Pubitemid 28094040)
2. ICH (1995). Guidance for Industry: S1A Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals.
3. ICH (2009). Addendum to ICH S6: Preclinical Safety Evaluation of Biotechology-Derived Pharmaceuticals: S6(R1).
4. ICH (2010). Guidance for Industry: S9 Nonclinical Evaluation for Anticancer Pharmaceuticals.
5. Le Tourneau C., Dieras V., Tresca P., Cacheux W., Paoletti X.. Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents. Target Oncol. 2010 ; 5: 65-72
6. Ponce R., Abad L., Amaravadi L., Gelzleichter T., Gore E., Green J., Gupta S., Herzyk D., Hurst C., Ivens I. A., Kawabata T., Maier C., Mounho B., Rup B., Shankar G., Smith H., Thomas P., Wierda D.. Immunogenicity of biologically derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol. 2009 ; 54: 164-82
7. Rosenfeldt H., Kropp T., Benson K., Ricci M. S., McGuinn W. D., Verbois S. L.. Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs. Toxicol Appl Pharmacol. 2010 ; 243: 125-33
8. Tomaszewski J. E.. Multi-species toxicology approaches for oncology drugs: the US perspective. Eur J Cancer. 2004 ; 40: 907-13 (Pubitemid 38519769)